Alnylam Pharmaceuticals 미래 성장

Future 기준 확인 6/6

Alnylam Pharmaceuticals (는) 각각 연간 70.3% 및 22.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 70% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 85.7% 로 예상됩니다.

주요 정보

70.3%

수익 성장률

70.0%

EPS 성장률

Biotechs 수익 성장	34.7%
매출 성장률	22.3%
향후 자기자본 수익률	85.7%
애널리스트 커버리지	Good
마지막 업데이트	16 Dec 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

LSE:0HD2 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	3,517	379	723	890	21
12/31/2025	2,638	-194	76	225	30
12/31/2024	2,239	-256	-30	-6	30
9/30/2024	2,095	-332	16	57	N/A
6/30/2024	2,344	-73	319	372	N/A
3/31/2024	2,003	-332	128	189	N/A
12/31/2023	1,828	-440	42	104	N/A
9/30/2023	1,724	-510	-67	2	N/A
6/30/2023	1,237	-1,064	-541	-473	N/A
3/31/2023	1,143	-1,065	-605	-537	N/A
12/31/2022	1,037	-1,131	-613	-541	N/A
9/30/2022	961	-1,182	-632	-559	N/A
6/30/2022	884	-981	-660	-578	N/A
3/31/2022	880	-893	-654	-577	N/A
12/31/2021	844	-853	-718	-642	N/A
9/30/2021	749	-838	-691	-615	N/A
6/30/2021	688	-887	-653	-591	N/A
3/31/2021	571	-876	-672	-604	N/A
12/31/2020	493	-858	-685	-615	N/A
9/30/2020	401	-891	-775	-688	N/A
6/30/2020	345	-846	-871	-760	N/A
3/31/2020	286	-886	-452	-336	N/A
12/31/2019	220	-886	-419	-278	N/A
9/30/2019	169	-821	-372	-233	N/A
6/30/2019	101	-858	-352	-204	N/A
3/31/2019	86	-802	-745	-595	N/A
12/31/2018	75	-761	-690	-563	N/A
9/30/2018	92	-692	-625	-515	N/A
6/30/2018	107	-570	N/A	-460	N/A
3/31/2018	93	-525	N/A	-438	N/A
12/31/2017	90	-491	N/A	-383	N/A
9/30/2017	69	-462	N/A	-358	N/A
6/30/2017	66	-443	N/A	-335	N/A
3/31/2017	59	-414	N/A	-324	N/A
12/31/2016	47	-410	N/A	-308	N/A
9/30/2016	37	-388	N/A	-282	N/A
6/30/2016	30	-361	N/A	-261	N/A
3/31/2016	30	-342	N/A	-247	N/A
12/31/2015	41	-290	N/A	-189	N/A
9/30/2015	58	-221	N/A	-173	N/A
6/30/2015	62	-188	N/A	-159	N/A
3/31/2015	61	-160	N/A	-150	N/A
12/31/2014	51	-360	N/A	-166	N/A
9/30/2014	37	-371	N/A	-151	N/A
6/30/2014	35	-357	N/A	-132	N/A
3/31/2014	37	-331	N/A	-109	N/A
12/31/2013	47	-89	N/A	-69	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 0HD2 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.1% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: 0HD2 (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: 0HD2 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: 0HD2 의 수익(연간 22.3% ) UK 시장( 3.6% 보다 빠르게 성장할 것으로 예상됩니다. 3.6% 연간).

고성장 수익: 0HD2 의 수익(연간 22.3% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 0HD2 의 자본 수익률은 3년 내에 매우 높을 것으로 예상됩니다( 85.7 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/22 19:54
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Alnylam Pharmaceuticals, Inc. 66 애널리스트 중 30 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Ishan Majumdar	Baptista Research
Huidong Wang	Barclays
Emily Bodnar	Berenberg

Alnylam Pharmaceuticals 미래 성장

Future 기준 확인 6/6

주요 정보

최근 미래 성장 업데이트

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Forecast to breakeven in 2026

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024

Forecast to breakeven in 2026

Recent updates

CEO & Director recently sold US$1.3m worth of stock

Alnylam Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Third quarter 2024 earnings released: US$0.87 loss per share (vs US$1.18 profit in 3Q 2023)

Alnylam Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Alnylam Pharmaceuticals, Inc. Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Alnylam Highlights New Data from Helios-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Alnylam Pharmaceuticals, Inc. Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

New minor risk - Shareholder dilution

Alnylam Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2024

Second quarter 2024 earnings released: US$0.13 loss per share (vs US$2.21 loss in 2Q 2023)

Alnylam Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

CEO & Director recently sold US$1.9m worth of stock

Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.52 loss per share (vs US$1.40 loss in 1Q 2023)

Alnylam Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives

CEO & Director recently sold US$1.0m worth of stock

Forecast to breakeven in 2026

Full year 2023 earnings released: US$3.53 loss per share (vs US$9.30 loss in FY 2022)

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024

Alnylam Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024

Forecast to breakeven in 2026

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$1.18 (vs US$3.32 loss in 3Q 2022)

Alnylam Pharmaceuticals, Inc. Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine

Alnylam Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Alnylam Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

No longer forecast to breakeven

Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

No longer forecast to breakeven

Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023

Second quarter 2023 earnings released: US$2.21 loss per share (vs US$2.30 loss in 2Q 2022)

Alnylam Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Alnylam Pharmaceuticals, Inc. Reports Updated Positive Interim Phase 1 Results for ALN-App, in Development for Alzheimer's Disease and Cerebral Amyloid Angiopathy

Forecast to breakeven in 2025

Alnylam Pharmaceuticals, Inc. Presents 18-Month Results from the Apollo-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings released: US$1.40 loss per share (vs US$2.00 loss in 1Q 2022)

CEO & Director recently sold US$1.5m worth of stock

No longer forecast to breakeven

Forecast to breakeven in 2025

Alnylam Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Alnylam Pharmaceuticals, Inc. Announces Board Changes

Alnylam Pharmaceuticals, Inc. Submits CTA Application for Aln-Khk, an Investigational RNAi therapeutic for the Treatment of Type 2 Diabetes

Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration for ONPATTRO® (Patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022

Third quarter 2022 earnings released: US$3.32 loss per share (vs US$1.72 loss in 3Q 2021)

Alnylam Pharmaceuticals, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. Presents Additional Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy At Heart Failure Society of America Annual Meeting

Alnylam Pharmaceuticals, Inc. Announces Executive Appointments

Alnylam Pharmaceuticals, Inc. Receives Approval in Europe for AMVUTTRA (Vutrisiran) for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals Announces Preliminary Phase 1 Data Supporting the Clinical Advancement of ALN-HSD

Alnylam Presents Positive Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

Alnylam Appoints Elliott Sigal, M.D., Ph.D., to Board of Directors

Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Forecast to breakeven in 2024

Alnylam Pharmaceuticals, Inc. Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

Alnylam Pharmaceuticals, Inc. to Report Q2, 2022 Results on Jul 28, 2022

No longer forecast to breakeven